Parexel

Parexel Named “Best Contract Research Organization” at 17th Annual Vaccine Industry Excellence (ViE) Awards

Retrieved on: 
Thursday, April 4, 2024
ChromeOS, Congress, Infection, Vie, Global health, Vaccine, MD, Senior, Master of Science, Parexel, Physician, Terrapin, Pharmaceutical industry

DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been named “Best Contract Research Organization” at the 17th Annual Vaccine Industry Excellence (ViE) Awards.

Key Points: 
  • DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been named “Best Contract Research Organization” at the 17th Annual Vaccine Industry Excellence (ViE) Awards.
  • Winners were named across 13 categories, including Best Contract Research Organization, which recognizes the role of CROs in supporting the development of safe and effective vaccines.
  • The annual ViE Awards, organized by Terrapin, celebrate the industry’s most outstanding achievements and showcase excellence in the global vaccine industry.
  • Parexel was recognized at the ViE Awards ceremony during the World Vaccine Congress on April 2 in Washington, D.C.

AI-based Clinical Trials Solution Provider Market Report 2024-2034, Featuring CONSILX, AiCure, Unlearn.AI, Trials.Ai, Intelligencia, Symphony AI, GNS Healthcare, Verily, BioSymetrics & BioAge Labs

Retrieved on: 
Saturday, March 30, 2024
Cloud, ChromeOS, Kyoto University, Attention, Google Cloud, Target, Cardiovascular disease, Software as a service, Forecasting, Prevalence, AstraZeneca, Drug discovery, Intelligence cycle, Incidence, RWE, Patient, 2.0, Biomarker, Research, Cancer, AI, Overalls, Fujitsu, Data collection, Medidata Solutions, Clinical trial, Parexel, Drug development, Artificial intelligence, USD, Medical device

Rising introduction of cutting-edge AI-based clinical trial platforms is predicted to boost the market growth during the forecast period.

Key Points: 
  • Rising introduction of cutting-edge AI-based clinical trial platforms is predicted to boost the market growth during the forecast period.
  • Its application in drug trials proves beneficial for enhancing the cost-effectiveness, clinical outcomes, and time efficiency of the drug development process, known for its resource-intensive nature.
  • This shift aims to optimize clinical outcomes while minimizing both the cost and time associated with drug trials.
  • Tara is specifically crafted to expedite the patient matching process with eligible clinical trials, resulting in enhanced recruitment at substantially reduced expenses.

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Monday, March 25, 2024
Catalent, Medical device, Temperature, Growth, Prevalence, Face, Molecule, Thermo Fisher Scientific, Medication, CTSL, Pharmacy, Partnership, Intelligence, Imp, Conditional sentence, ICON, Global health, Research, Good manufacturing practice, IMP, Transport, ICON PLC, Placebo, Infosys, GMP, Excipient, Investment, Clinical trial, GDP, Drug development, API, Clinical data management, Table, Ageing, Parexel

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Monday, March 25, 2024
Catalent, Medical device, Temperature, Growth, Prevalence, Face, Molecule, Thermo Fisher Scientific, Medication, CTSL, Pharmacy, Partnership, Intelligence, Imp, Conditional sentence, ICON, Global health, Research, Good manufacturing practice, IMP, Transport, ICON PLC, Placebo, Infosys, GMP, Excipient, Investment, Clinical trial, GDP, Drug development, API, Clinical data management, Table, Ageing, Parexel

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Bioforum Expands Leadership Team with Appointment of Michael Goedde as President

Retrieved on: 
Tuesday, March 19, 2024
Automation, ChromeOS, Sanofi, Development, MedImmune, NESS, ICON PLC, Database, CLZ, Goedde, Trustee, CNS, ICON, Biostatistics, Research, Hoechst AG, Society, SDTM, BioGRID, Human Genome Sciences, Parexel, Nursing

NESS ZIONA, Israel, March 19, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the appointment of Michael Goedde as its President. A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy. 

Key Points: 
  • A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.
  • "As we expand our presence in North America and around the world, I'm delighted to welcome Michael to the Bioforum family and confident that his leadership will be invaluable in driving our long-term growth and success."
  • Prior to ICON, Goedde spent four years at Parexel in roles of increasing responsibility, most recently as Vice President of Global Data Operations.
  • He holds a bachelor's degree in computer science from Computer Lern Zentrum (CLZ) Hoechst AG in Frankfurt, Germany.

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

Retrieved on: 
Thursday, March 7, 2024
OBE, GSK, Prostate cancer, Parexel, Conference, Human, Sanofi, Patient, MPH, Medicine, Pharmaceutical industry

NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 8th annual Patients as Partners® Europe meeting, taking place May 14-15, 2024, at Plaisterers' Hall, in London, England. Patients as Partners® Europe offers an unparalleled opportunity to hear from pharma R&D and patient advocacy on how patient involvement gets done to drive greater efficiencies and inclusivity in clinical research with better outcomes.

Key Points: 
  • Patients as Partners® Europe announces its dates, keynotes and topics for the London meeting which is attended by pharma and biotech R&D, patient advocacy, and technologists to include and empower the patient voice for greater efficiencies in medicine development.
  • NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 8th annual Patients as Partners® Europe meeting, taking place May 14-15, 2024, at Plaisterers' Hall, in London, England.
  • Patients as Partners® Europe offers an unparalleled opportunity to hear from pharma R&D and patient advocacy on how patient involvement gets done to drive greater efficiencies and inclusivity in clinical research with better outcomes.
  • "Patients as Partners® Europe presents case examples on how patient involvement in clinical research can accelerate medicine development, how it can improve better access, inclusivity and diversity," said Valerie Bowling, Executive Director
    "Patients as Partners Europe brings advocates and sponsors together in a unique forum focused on improving collaborations that result in meaningful impact for patients," said 2024 co-chair, Victoria DiBiaso, MPH, Global Head, Patient Informed Development & Health Value Translation, Sanofi.

Advarra Bolsters Executive Leadership Team to Support Growing Global Demand for a Connected Clinical Trials Ecosystem

Retrieved on: 
Tuesday, January 30, 2024
ChromeOS, Patient, General counsel, Ethics, Lilly, CFO, Capasso, Thermo Fisher Scientific, Risk management, Information technology, Pirkei Avot, News, Parexel

COLUMBIA, Md., Jan. 30, 2024 /PRNewswire/ -- Advarra, the market leader in regulatory review solutions and clinical research technology for sites and sponsors, announced the hiring of finance and operations leader Dwight Van Inwegen as Chief Financial Officer (CFO) and pharmaceutical industry veteran Marco Capasso as General Counsel and Secretary of the Board. With deep industry expertise, the new executives will help Advarra scale internal processes and global growth, speeding its mission to connect the clinical research landscape and accelerate trial outcomes.

Key Points: 
  • With deep industry expertise, the new executives will help Advarra scale internal processes and global growth, speeding its mission to connect the clinical research landscape and accelerate trial outcomes.
  • He has more than 30 years of senior-level leadership experience in finance and operations, successfully building and scaling finance organizations globally.
  • "I'm excited to help accelerate the tremendous growth that has already made Advarra a market leader and go-to partner in clinical research," said Van Inwegen.
  • Prior to joining Advarra, Capasso was General Counsel at WCG Clinical and held leadership positions at several leading life sciences companies including Lilly and Parexel.

Pharmaceutical Contract Research and Manufacturing (CRAM) Market size to grow by USD 121.35 billion from 2022 to 2027; Asia to account for 41% of market growth - Technavio

Retrieved on: 
Tuesday, January 16, 2024
ChromeOS, Catalent, Recipharm, Parexel, ROW, Geography, Biotechnology, Syneos Health, Thermo Fisher Scientific, ICON PLC, ICON, CMO, CRAM, USD, Free, Lupin Limited, Research, IQVIA, Growth, Fine chemical

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.
  • In addition, the momentum of the market will progress at a CAGR of 10.32% during the forecast period, according to Technavio Research.
  • For additional data on Market Size (2017) Historic Year, Market Size - Forecasted Year, Historic Opportunity (2017-2021), Historic CAGR, Forecasted Opportunity (2023-2027), Market Opportunity Transformation Growth, and Market Opportunity Capitalization.
  • Pharmaceutical Contract Research And Manufacturing (CRAM) Market: Segmentation Analysis
    The market share growth of the CMO segment will be significant during the forecast period.

Parexel and Japanese Foundation for Cancer Research Announce Strategic Alliance

Retrieved on: 
Wednesday, January 10, 2024
ChromeOS, Patient, Medicine, Incidence, MD, FRCS, Cancer, Osaka International Cancer Institute, Parexel, Doctor of Philosophy, Organization, Clinical trial, JFCR, Pharmaceutical industry

DURHAM, N.C. and TOKYO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Parexel , one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, today announced a strategic alliance to accelerate access to oncology clinical trials in Japan.

Key Points: 
  • DURHAM, N.C. and TOKYO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Parexel , one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, today announced a strategic alliance to accelerate access to oncology clinical trials in Japan.
  • Under the agreement, JFCR will join Parexel’s Global Site Alliance network, making it a preferred site for oncology clinical trials and providing more opportunities for Japanese patients to participate in cancer research.
  • JFCR’s therapeutic expertise in combination with Parexel’s clinical research experience will enable both organizations to efficiently recruit Japanese patients often underrepresented in oncology research while expanding cancer care options in Japan.
  • Parexel maintains relationships with other leading alliance sites in the region, including Kyoto University Hospital, Osaka International Cancer Institute, Beijing Illness Challenge Foundation and the Cancer Hospital Chinese Academy of Medical Sciences.

$22.4 Bn Pharmacovigilance Global Market Opportunities and Strategies to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Health, Pharmaceutical, Conditional sentence, ADR, IQVIA, Research, Incidence, Hospital, Pharmacovigilance, Developed country, Mining, Accenture, Drug development, ICON PLC, Parexel, Prevalence, Disulfiram-like drug, Clinical trial, Cognizant, Wipro, Ageing, EHR, Growth

The "Pharmacovigilance Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacovigilance Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.
  • The spontaneous reporting market was the largest segment of the pharmacovigilance market by type, accounting for $2.2 billion or 32.8% of the total market in 2022.
  • North America was the largest region in the pharmacovigilance market, accounting for 44.0% of the global market in 2022.
  • The global pharmacovigilance market is fragmented, with a large number of players operating in the market.